[1]
|
Gonzalez, H., Olsson, T. and Borg, K. (2010) Manage- ment of postpolio syndrome. The Lancet Neurology, 9, 634-642. doi:10.1016/S1474-4422(10)70095-8
|
[2]
|
Trojan, D.A. and Cashman, N.R. (2005) Post-poliomye- litis syndrome. Muscle Nerve, 31, 6-19.
doi:10.1002/mus.20259
|
[3]
|
Werhagen, L. and Borg, K. (2010) Analysis of long- standing nociceptive and neuropathic pain in patients with post-polio syndrome. Journal of Neurology, 257, 1027- 1031. doi:10.1007/s00415-010-5456-0
|
[4]
|
Farbu, E., Rekand, T., Vik-Mo, E., Lygren, H., Gilhus, N.E. and Aarli, J.A. (2007) Post-polio syndrome patients treated with intravenous immunoglobulin: A double- blinded randomized controlled pilot study. European Jour- nal of Neurology, 14, 60-65.
doi:10.1111/j.1468-1331.2006.01552.x
|
[5]
|
Willén, C. and Grimby, G. (1998) Pain, physical activity, disability in individuals with late effects of polio. Ar- chives of Physical Medicine and Rehabilitation, 79, 915- 919. doi:10.1016/S0003-9993(98)90087-9
|
[6]
|
Widar, M. and Ahlstr?m, G. (1999) Pain in persons with post-polio. The Swedish version of the Multidimensional Pain Inventory (MPI). Scandinavian Journal of Caring Science, 13, 33-40.
|
[7]
|
Werhagen, L. and Borg, K. (2011) Effect of intravenous immunoglobulin on pain in patients with post-polio syn- drome. Journal of Rehabilitation Medicine, 43, 1038- 1040. doi:10.2340/16501977-0884
|
[8]
|
March of Dimes. Post-polio syndrome: Identifying best practice in diagnosis and care.
http://www.marchofdimes.com/downloads/PostPolio.pdf
|
[9]
|
Gonzalez, H., Khademi, M., Andersson, M., Wallstr?m, E., Borg, K. and Olsson, T. (2002) Prior poliomyelitis— Evidence of cytokine production in the central nervous system. Journal of the Neurological Sciences, 205, 9-13.
doi:10.1016/S0022-510X(02)00316-7
|
[10]
|
Gonzalez, H., Khademi, M., Andersson, M., Piehl, F., Wallstr?m, E., et al. (2004) Prior poliomyelitis—IvIg treat- ment reduces proinflammatory cytokine production. Jour- nal of Neuroimmunology, 150, 139-144.
doi:10.1016/j.jneuroim.2004.01.010
|
[11]
|
Fordyce, C.B., Gagne, D., Jalili, F., alatab, S., Arnold, D.L., Da Costa, D., Sawoszczuk, S., Bodner, C., Shapiro, S., Collet, J.-P., Robinson, A., Le Cruguel, J.-P., Lapierre, Y., Bar-Or, A. and Trojan, D.A. (2008) Elevated serum in- flammatory markers in post-poliomyelitis syndrome. Jour- nal of Neurological Sciences, 271, 80-86.
doi:10.1016/j.jns.2008.03.015
|
[12]
|
Gonzalez, H., Khademi, M., Borg, K. and Olsson, T. (2012) Intravenous immunoglobulin treatment of the post- polio syndrome: Sustained effects on quality of life vari- ables and cytokine expression after one year follow-up. Journal of Neuroinflammation, 9, 167.
doi:10.1186/1742-2094-9-167
|
[13]
|
Gonzalez, H., Stibrant-Sunnerhagen, K., Sj?berg, I., Kapanoides, G., Olsson, T. and Borg, K. (2006) Intravenous immunoglobulin for post-polio syndrome: A randomised controlled trial. Lancet Neurology, 5, 493-500.
doi:10.1016/S1474-4422(06)70447-1
|
[14]
|
Kaponides, G., Gonzalez, H., Olsson, H. and Borg, K. (2006) Effect of intravenous immunoglobulin in patients with post-polio syndrome—An uncontrolled pilot study. Journal of Rehabilitation Medicine, 38, 138-140.
doi:10.1080/16501970500441625
|